These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25743991)

  • 21. Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.
    Peter J; Nelson DR
    Liver Int; 2015 Jan; 35 Suppl 1():65-70. PubMed ID: 25529089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment].
    Kwon JH
    Korean J Gastroenterol; 2015 Aug; 66(2):131-3. PubMed ID: 26513826
    [No Abstract]   [Full Text] [Related]  

  • 23. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan.
    Liu CH; Yu ML; Peng CY; Hsieh TY; Huang YH; Su WW; Cheng PN; Lin CL; Lo CC; Chen CY; Chen JJ; Ma Q; Brooks-Rooney C; Kao JH
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1290-1300. PubMed ID: 30362139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ledipasvir/Sofosbuvir administration achieves very high rate of viral clearance in patients with HCV genotype 1 infection without cirrhosis, regardless of ribavirin co-administration or length of treatment.
    Gentile I; Borgia G
    Evid Based Med; 2014 Dec; 19(6):223-4. PubMed ID: 25028605
    [No Abstract]   [Full Text] [Related]  

  • 25. Two Antiviral Drugs Approved For Adolescents With HCV.
    Aschenbrenner DS
    Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749879
    [No Abstract]   [Full Text] [Related]  

  • 26. Simultaneous targeted therapy for metastatic melanoma and hepatitis C.
    Kofler L; Berg C; Kofler K; Geipel A; Lipp HP; Müller A; Eigentler T; Forschner A
    J Dtsch Dermatol Ges; 2020 Jan; 18(1):42-43. PubMed ID: 31538700
    [No Abstract]   [Full Text] [Related]  

  • 27. Healing of autoimmune hepatitis associated with hepatitis C virus infection treated with direct-acting antivirals.
    López Couceiro L; Gómez Domínguez E; Muñoz Gómez R; Castellano Tortajada G; Ibarrola de Andrés C; Fernández Vázquez I
    Rev Esp Enferm Dig; 2019 Feb; 111(2):159-161. PubMed ID: 30449122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gilead's interferon-free HCV combo approved.
    Nat Biotechnol; 2014 Nov; 32(11):1070. PubMed ID: 25380423
    [No Abstract]   [Full Text] [Related]  

  • 29. Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
    Sofia MJ
    Antiviral Res; 2014 Jul; 107():119-24. PubMed ID: 24792751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Considerations on bringing warehoused HCV patients into active care following interferon-free, direct-acting antiviral drug approval.
    Palak A; Livoti C; Audibert C
    Postgrad Med; 2017 May; 129(4):471-475. PubMed ID: 28277812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.
    Younossi ZM; Jiang Y; Smith NJ; Stepanova M; Beckerman R
    Hepatology; 2015 May; 61(5):1471-8. PubMed ID: 25706754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kidney transplant recipients with hepatitis C virus experienced 100% sustained virologic response at 12 weeks when treated with sofosbuvir-ledipasvir.
    Sise ME
    Hepatology; 2017 Oct; 66(4):1335-1337. PubMed ID: 28650558
    [No Abstract]   [Full Text] [Related]  

  • 33. Evidence of HCV recovery after therapy of hepatitis C virus infection by direct acting antivirals.
    Parlati L; Sirmai L; Dupuy CA; Glotz D; Pol S
    Clin Res Hepatol Gastroenterol; 2019 Apr; 43(2):e18-e19. PubMed ID: 30293896
    [No Abstract]   [Full Text] [Related]  

  • 34. Role of Direct-Acting Antivirals in Hepatitis C Virus-Positive Castleman Disease.
    Tahir M; Charles L
    Am J Ther; 2018; 25(6):e733-e734. PubMed ID: 29557805
    [No Abstract]   [Full Text] [Related]  

  • 35. Disappearance of multiple hyperechoic liver nodules in sporadic porphyria cutanea tarda after treatment with ledipasvir/sofosbuvir for hepatitis C.
    Takata K; Shakado S; Sakamoto K; Fukuda H; Yamauchi R; Fukuda S; Kunimoto H; Umeda K; Tanaka T; Yokoyama K; Morihara D; Takeyama Y; Irie M; Sakisaka S
    Clin J Gastroenterol; 2017 Oct; 10(5):459-463. PubMed ID: 28884440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging options for treating hepatitis C infection.
    Fantasia HC
    Nurs Womens Health; 2015; 19(2):183-7. PubMed ID: 25900589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incorporating patient-reported outcomes into hepatitis C virus treatment studies.
    Evon DM
    Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1360-2. PubMed ID: 24534544
    [No Abstract]   [Full Text] [Related]  

  • 38. New Rule Requires Some Physicians to Report on Postoperative Visits.
    Pullen LC
    Am J Transplant; 2017 Apr; 17(4):847-848. PubMed ID: 28371537
    [No Abstract]   [Full Text] [Related]  

  • 39. [Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():53. PubMed ID: 25026860
    [No Abstract]   [Full Text] [Related]  

  • 40. Trials wrap on interferon-free hepatitis C regimen.
    Dalzell MD
    Manag Care; 2013 Apr; 22(4):41-2. PubMed ID: 23678562
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.